Fig. 1.
HCF immunization protects against LL/2 tumor growth both in prophylactic and therapeutic settings. a C57BL/6 J male mice (n = 6) were s.c. vaccinated three times in two week-intervals with human HCF (300 μg) or PBS in alum before LL/2 cell challenge (100,000 cells/mouse). Tumor growth was measured regularly using a caliper. Tumor volume (mm3) was calculated according to the following formula: 4/3 × pi × r1 × r2 × r3. b Survival of vaccinated and control mice was followed for 120 days after tumor challenge. Mice were euthanized when subcutaneous tumors reached 20 mm or when mice shows signs of distress or discomfort. c After s.c. administration of LL/2 cells (day 0), C57BL/6 J male? mice (n = 6) received a 300 μg dose of human HCF or PBS in alum on days 4, 7, and 11. d Survival of treated and control mice was followed for 90 days after tumor challenge. The data are representative of at least three independent experiments